Meeting
2022 ASCO Annual Meeting
Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.
Authors
Laura Spring
Massachusetts General Hospital Cancer Center, Boston, MA
Laura Spring , Sara M. Tolaney , Neelam Vijay Desai , Geoffrey Fell , Lorenzo Trippa , Amy H. Comander , Therese Marie Mulvey , Shannon McLaughlin , Phoebe Ryan , Aron S. Rosenstock , Ana Christina Garrido-Castro , Filipa Lynce , Beverly Moy , Steven J. Isakoff , Nadine M. Tung , Elizabeth A. Mittendorf , Leif W. Ellisen , Aditya Bardia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT04230109
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 512)
DOI
10.1200/JCO.2022.40.16_suppl.512
Abstract #
512
Poster Bd #
284
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Results of randomized phase II trial of neoadjuvant carboplatin plus docetaxel or carboplatin plus paclitaxel followed by AC in stage I-III triple-negative breast cancer (NCT02413320).
First Author: Priyanka Sharma
Poster
2023 ASCO Annual Meeting
Taxane combined with lobaplatin or anthracycline for neoadjuvant treatment of triple-negative breast cancer: A single-center, randomized, controlled, phase-II clinical study.
First Author: Cheng Wang
Poster
2020 ASCO Virtual Scientific Program
Neoadjuvant docetaxel + carboplatin versus epirubicin+cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label, phase II trial.
First Author: Liulu Zhang
Poster
2020 ASCO Virtual Scientific Program
Neoadjuvant TCH (docetaxel/darboplatin/trastuzumab) versus EC-TH (epirubicin/cyclophosphamide followed by docetaxel/ trastuzumab ) in patients with HER2-positive breast cancer (neoCARH): A randomised, open-label, multicenter, phase II trial.
First Author: Hong-Fei Gao